These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 37381714

  • 1. Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma.
    Fu D, Yan J, Zhang Z, Liu Y, Ma X, Ding J, Yang S, Zhao R, Chang A, Gao C, Liu J, Zhao T, Wang X, Huang C, Gao S, Ma Y, Tang B, Feng Y, Wang H, Hao J.
    Cancer Biol Med; 2023 Jun 27; 20(8):599-626. PubMed ID: 37381714
    [Abstract] [Full Text] [Related]

  • 2. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
    Xian G, Zhao J, Qin C, Zhang Z, Lin Y, Su Z.
    Cancer Lett; 2017 Jan 28; 385():65-74. PubMed ID: 27840243
    [Abstract] [Full Text] [Related]

  • 3. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H, Gao W, Li X, Yu L, Luo D, Liu Y, Yu X.
    Pancreatology; 2021 Apr 28; 21(3):589-598. PubMed ID: 33579599
    [Abstract] [Full Text] [Related]

  • 4. Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells.
    Calabretta S, Bielli P, Passacantilli I, Pilozzi E, Fendrich V, Capurso G, Fave GD, Sette C.
    Oncogene; 2016 Apr 21; 35(16):2031-9. PubMed ID: 26234680
    [Abstract] [Full Text] [Related]

  • 5. MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance.
    Dash S, Ueda T, Komuro A, Amano H, Honda M, Kawazu M, Okada H.
    Mol Cancer Res; 2023 May 01; 21(5):444-457. PubMed ID: 36757299
    [Abstract] [Full Text] [Related]

  • 6. Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion.
    Sumiyoshi H, Matsushita A, Nakamura Y, Matsuda Y, Ishiwata T, Naito Z, Uchida E.
    Oncol Rep; 2016 Jun 01; 35(6):3216-26. PubMed ID: 27035235
    [Abstract] [Full Text] [Related]

  • 7. Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway.
    Adesso L, Calabretta S, Barbagallo F, Capurso G, Pilozzi E, Geremia R, Delle Fave G, Sette C.
    Oncogene; 2013 Jun 06; 32(23):2848-57. PubMed ID: 22797067
    [Abstract] [Full Text] [Related]

  • 8. Tumor-derived interleukin 35 mediates the dissemination of gemcitabine resistance in pancreatic adenocarcinoma.
    Sun H, Ge Y, Liu J, Li Z, Li H, Zhao T, Wang X, Feng Y, Wang H, Gao S, Shi L, Yang S, Sun P, Chang A, Hao J, Huang C.
    Oncogene; 2024 Mar 06; 43(11):776-788. PubMed ID: 38243080
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
    Xu D, Cobb MG, Gavilano L, Witherspoon SM, Williams D, White CD, Taverna P, Bednarski BK, Kim HJ, Baldwin AS, Baines AT.
    Cancer Biol Ther; 2013 Jun 06; 14(6):492-501. PubMed ID: 23760491
    [Abstract] [Full Text] [Related]

  • 10. TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770-5p axis in PDAC.
    Huang W, Hu X, He X, Pan D, Huang Z, Gu Z, Huang G, Wang P, Cui C, Fan Y.
    Drug Resist Updat; 2024 May 06; 74():101079. PubMed ID: 38518727
    [Abstract] [Full Text] [Related]

  • 11. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
    Kubo M, Gotoh K, Eguchi H, Kobayashi S, Iwagami Y, Tomimaru Y, Akita H, Asaoka T, Noda T, Takeda Y, Tanemura M, Mori M, Doki Y.
    Ann Surg Oncol; 2020 Feb 06; 27(2):610-619. PubMed ID: 31605325
    [Abstract] [Full Text] [Related]

  • 12. MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.
    Dhayat SA, Mardin WA, Seggewiß J, Ströse AJ, Matuszcak C, Hummel R, Senninger N, Mees ST, Haier J.
    PLoS One; 2015 Feb 06; 10(11):e0143755. PubMed ID: 26606261
    [Abstract] [Full Text] [Related]

  • 13. Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Ma L, Fan Z, Du G, Wang H.
    Biochem Biophys Res Commun; 2019 Feb 12; 509(3):845-853. PubMed ID: 30638935
    [Abstract] [Full Text] [Related]

  • 14. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
    Yang D, Shi J, Fu H, Wei Z, Xu J, Hu Z, Zhang Y, Yan R, Cai Q.
    Tumour Biol; 2016 Sep 12; 37(9):12315-12327. PubMed ID: 27289231
    [Abstract] [Full Text] [Related]

  • 15. Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells.
    Lu C, Yang D, Sabbatini ME, Colby AH, Grinstaff MW, Oberlies NH, Pearce C, Liu K.
    BMC Cancer; 2018 Feb 06; 18(1):149. PubMed ID: 29409480
    [Abstract] [Full Text] [Related]

  • 16. SNHG14 enhances gemcitabine resistance by sponging miR-101 to stimulate cell autophagy in pancreatic cancer.
    Zhang X, Zhao P, Wang C, Xin B.
    Biochem Biophys Res Commun; 2019 Mar 19; 510(4):508-514. PubMed ID: 30737032
    [Abstract] [Full Text] [Related]

  • 17. LncRNA TUG1 promoted viability and associated with gemcitabine resistant in pancreatic ductal adenocarcinoma.
    Yang F, Li X, Zhang L, Cheng L, Li X.
    J Pharmacol Sci; 2018 Jun 19; 137(2):116-121. PubMed ID: 29960845
    [Abstract] [Full Text] [Related]

  • 18. YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer.
    Li B, Xing F, Wang J, Wang X, Zhou C, Fan G, Zhuo Q, Ji S, Yu X, Xu X, Qin Y, Li Z.
    Cancer Lett; 2024 Oct 10; 602():217197. PubMed ID: 39216548
    [Abstract] [Full Text] [Related]

  • 19. Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer.
    Qian W, Li J, Chen K, Jiang Z, Cheng L, Zhou C, Yan B, Cao J, Ma Q, Duan W.
    Life Sci; 2018 Sep 01; 208():253-261. PubMed ID: 30053447
    [Abstract] [Full Text] [Related]

  • 20. Micro-RNA-21 Regulates Cancer-Associated Fibroblast-Mediated Drug Resistance in Pancreatic Cancer.
    Zhang L, Yao J, Li W, Zhang C.
    Oncol Res; 2018 Jul 05; 26(6):827-835. PubMed ID: 28477403
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.